Actuate Therapeutics Inc

NASDAQ:ACTU

Biotechnology

Healthcare
$2.09 +2.96%

+$0.06 today

Market cap
$50.01M
Beta
0.53
P/E (TTM)
-2.3
EPS (TTM)
-$0.92
52W Low $1.58High $9.22

Volume 0.03M

Average 0.16M

ACTU Operating Expenses

Total costs of running the business that are not directly tied to producing goods or services sold.

Actuate Therapeutics IncNASDAQ: ACTU

Operating Expenses · Q1 FY2026 · quarter ended Mar 2026

Operating expenses declines year over year

Q1 FY2026 operating expenses of $5.71M fell 10.4% year over year, behind the -8.1% change in trailing-twelve-month operating expenses. Sequentially, it rose 21.7% from the prior quarter. Over 3 fiscal years it compounded at +3.6% a year.

Context

  • Operating expenses increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -10.4% toward the trailing-twelve-month pace of -8.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$5.71M+21.7% QoQ
Last fiscal yearDec 2025
$22.5M-10.6% YoY
LTMMar 2026
$21.83M-8.1% YoY
Operating Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-10.4%——
1 year-10.6%——
3-year CAGR+3.6%——
5-year CAGR——
10-year CAGR——

Operating Expenses history

USD · from the income statement

Latest · FY2025
22.5M USD
Year-over-year change
-10.6%
3-year CAGR
+3.6%

Operating Expenses vs competitors

How ACTU compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating expenses is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -8.1% is the 4th highest of 9, against a peer median of -14.8%.
  • Over three fiscal years its annual growth of +3.6% compares with a peer median of -6.6%.
ACTU Competitors
Operating Expenses for ACTU and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VORVor Biopharma Inc.LTM Mar 2026$373.48M USD+210.2%+63.9%—
ALECAlector, Inc.LTM Mar 2026$125.25M USD-17.6%-16.6%680.1%
NKTXNkarta, Inc.LTM Mar 2026$113.97M USD-13.7%-2.0%—
MCRBSeres Therapeutics, Inc.LTM Mar 2026$87.4M USD-16.0%-20.4%7620.1%
PEPGPepGen Inc.LTM Mar 2026$79.52M USD-27.0%+10.5%—
MOLNMolecular Partners AGLTM Mar 2026CHF 63.08M CHF+100.0%-11.3%—
SPROSpero Therapeutics, Inc.LTM Mar 2026$41.26M USD+410.9%-13.1%75.3%
ELTXElicio Therapeutics, Inc.LTM Mar 2026$37.29M USD-15.8%+17.3%—
ACTUActuate Therapeutics IncLTM Mar 2026$21.83M USD-8.1%+3.6%—
Peer median (excluding ACTU) —-14.8%-6.6%680.1%

Competitors are the stored peer set for ACTU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0000
Cost of Revenue0000
Gross Profit0000
Gross Margin————
Research & Development16.39M21.71M18.68M10.29M
Selling, General & Admin3.82M3.27M6.48M12.2M
Operating Expenses20.21M24.97M25.16M22.5M
Depreciation & Amortization63.61K272.85K2.14M0
EBITDA(20.08M)(24.43M)(25.16M)(22.21M)
EBITDA Margin————
Operating Income(20.21M)(24.97M)(25.16M)(22.5M)
Operating Margin————
Interest Income27.03K352.67K222.29K287.71K
Interest Expense16.2K43.64K(18.72K)20.25K
Other Income / Expenses47.41K229.21K(2.12M)267.46K
Income Before Tax(20.16M)(24.74M)(27.28M)(22.23M)
Pre-Tax Margin————
Income Tax Expense008000
Net Income(20.16M)(24.74M)(27.29M)(22.23M)
Net Margin————
EPS (Basic)(1.34)(1.65)(3.26)(1.06)
EPS (Diluted)(1.34)(1.65)(3.26)(1.06)
Weighted Avg Shares15.03M15.03M19.51M21.02M
Weighted Avg Shares (Diluted)15.03M15.03M19.51M21.02M

Actuate Therapeutics Inc

NASDAQ:ACTU

Intrinsic Alpha fair value

Locked

Current Price

$2.09

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.